Amivantamab and Mobocertinib in Exon 20 insertions EGFR Mutant Lung Cancer, Challenge To The Current Guidelines

In 2021, the US Food and Drug Administration (FDA) approved two drugs targeting exon 20 directly: amivantamab and mobocertinib, under the accelerated approval pathway, for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGF...

Descripción completa

Detalles Bibliográficos
Autores principales: Olivier, Timothée, Prasad, Vinay
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2022
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9256830/
https://www.ncbi.nlm.nih.gov/pubmed/35785671
http://dx.doi.org/10.1016/j.tranon.2022.101475

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9256830/
https://www.ncbi.nlm.nih.gov/pubmed/35785671
http://dx.doi.org/10.1016/j.tranon.2022.101475

Ejemplares similares